Episode 3: Cost and Access
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Episode 3: Cost and Access
-
ナレーター：
-
著者：
このコンテンツについて
In this episode of Beyond the Scale: The Ozempic Effect, hosts Terry Turner and Christian Simmons explore the high cost of GLP-1 medications like Ozempic and Wegovy — and why many Americans still can’t afford them.
Former Congressman Robert Andrews, a key architect of the Affordable Care Act and now CEO of the Health Transformation Alliance, explains why these medications remain so expensive and what it would take to bring prices down.
Pharmacist and Liviniti co-founder Dr. Steven Boyd takes listeners behind the scenes of the drug pricing system, shedding light on the role pharmacy benefit managers (PBMs) play in driving up costs — and how employers are pushing back to make coverage more transparent and affordable.
Clinical pharmacist Dr. Elizabeth Van Dril returns to discuss the risks of compounded GLP-1 drugs, often sold at lower prices but without FDA approval or consistent quality. If you’re wondering who gets access to these life-changing medications — and why — this episode breaks it down.
Learn more at Drugwatch.com.